Joining host Dr. Alan Brown is Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology of the Division of Medicine-Endocrinology and Metabolism at Duke University School of Medicine. Their discussion will focus on data and results from HPS-2 THRIVE, a large-scale study comparing the use of statins and niacin versus statins alone. THRIVE stands for the Treatment of HDL to Reduce the Incidence of Vascular Events.
HPS-2 THRIVE Data and Results
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Joining host Dr. Alan Brown is Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology of the Division of Medicine-Endocrinology and Metabolism at Duke University School of Medicine. Their discussion will focus on data and results from HPS-2 THRIVE, a large-scale study comparing the use of statins and niacin versus statins alone. THRIVE stands for the Treatment of HDL to Reduce the Incidence of Vascular Events.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Updates From the 7th World Symposium Task Force
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?